HER3 Alterations in Cancer and Potential Clinical Implications
Open accessThe DOI matches its Crossref record; 152 of the 155 references it cites were found in a registry or an index.
Abstract
In recent years, the third member of the HER family, kinase impaired HER3, has become a target of interest in cancer as there is accumulating evidence that HER3 plays a role in tumor growth and progression. This review focuses on HER3 activation in bladder, breast, colorectal, and lung cancer disease progression. HER3 mutations occur at a rate up to ~10% of tumors dependent on the tumor type. With patient tumors routinely sequenced for gene alterations in recent years, we have focused on HER3 mutations in bladder, breast, colon, and lung cancers particularly in response to targeted therapies and the potential to become a resistance mechanism. There are currently several HER3 targeting drugs in the pipeline, possibly improving outcomes for cancer patients with tumors containing HER3 activation and/or alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 The frequency of HER3 alterations as seen in bladder (n = 2419), breast (n = 8615), colorectal (n = 4453), and lung (n = 7204) cancers across different subtypes and multiple nonredundant studies. Figure rendered using cBioPortal [27,28].](https://figures.cochat.ai/paper-figures/5b93db90b4904b04a3c573ed6bfc2f23/her3-alterations-in-cancer-and-potential-clinical-implications-figure-2.jpg)
![Figure 3 The frequency of HER3 mutations in bladder cancer and their locations within the receptor. Figure rendered in cBioPortal using multiple studies (n = 2419). Gray indicates truncating mutation, green indicates a missense mutation, yellow indicates splice mutation, and brown indicates an in-frame mutation [27,28].](https://figures.cochat.ai/paper-figures/39d388b75d2b497c9454b0e267af427c/her3-alterations-in-cancer-and-potential-clinical-implications-figure-3.jpg)
![Figure 4 The frequency of HER3 mutations in breast cancer and their locations within the receptor. Figure rendered in cBioPortal using multiple studies (n = 8615). Gray indicates truncating mutation, green indicates a missense mutation, yellow indicates splice mutation, and brown indicates an in-frame mutation [27,28].](https://figures.cochat.ai/paper-figures/9079f5476f534a9b9c87c4c63ac0d3e1/her3-alterations-in-cancer-and-potential-clinical-implications-figure-4.jpg)
![Figure 5 The frequency of HER3 mutations in colorectal cancer and their locations within the receptor. Figure rendered in cBioPortal using multiple studies (n = 4453). Gray indicates truncating mutation, green indicates a missense mutation, yellow indicates splice mutation, and brown indicates an in-frame mutation [27,28].](https://figures.cochat.ai/paper-figures/c4357cb7ed5849249056938487be8817/her3-alterations-in-cancer-and-potential-clinical-implications-figure-5.jpg)
![Figure 6 The frequency of HER3 mutations in lung cancer and their locations within the HER3 receptor. Figure rendered in cBioPortal using multiple studies (n = 7204). Gray indicates truncating mutation, green indicates a missense mutation, yellow indicates splice mutation, and brown indicates an in-frame mutation [27,28].](https://figures.cochat.ai/paper-figures/8e09d8ba85364a19bf6f126a157f2cae/her3-alterations-in-cancer-and-potential-clinical-implications-figure-6.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HER3 displays intrinsically low kinase activity and must dimerize with either another EGFR-family member, including HER2 and EGFR, or a non-EGFR receptor tyrosine kinase (RTKs), including fibroblast growth factor receptor (FGFR), MET, or Axl to stimulate cell survival and proliferation signaling [38].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196 · cited 3×
“Slightly more common in men and older populations, the overall 5-year survival rate for colon cancer is 63% [87].”
BackgroundInfluentialIntegrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 4×
“Later studies showed that certain HER3 mutations were found to be oncogenic, and in recent years, further papers have focused on the role mutant HER3 and other HER3 alterations play in different types of cancers [26,29,30].”
BackgroundInfluentialTriple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0111-2 · Cited by 3,024
Olayioye, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,434
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism
Hoxhaj, G., & Manning, B. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0216-7 · Cited by 2,137 · cited 2×
“Taken together HER3 can activate the PI3K/Akt pathway, which is significant for cancer cell survival and metabolism [24] and the MAPK pathway, inciting cell proliferation [25].”
BackgroundLenis, A. T., Lec, P. M., Chamie, K., & MSHS, M. (2020) · JAMA · doi:10.1001/jama.2020.17598 · Cited by 2,051
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967 · cited 1×
“Comprising roughly 16% of all breast cancers, triple negative breast cancer lacks the expression of ER, PR, or HER2 and has a high heterogenous nature between patients [49].”
BackgroundAACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028485 · Cited by 1,711
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, H.-S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,612
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Loriot, Y., Necchi, A., Park, S. H., Garcia-Donas, J., Huddart, R., Burgess, E., Fleming, M., Rezazadeh, A., Mellado, B., Varlamov, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817323 · Cited by 1,360
Self-citationCrystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains
Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J.-H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00963-7 · Cited by 1,227
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,036
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967
Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F., & Hynes, N. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1537685100 · Cited by 950
A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
Braicu, C., Buse, M., Busuioc, C., Drula, R., Gulei, D., Raduly, L., Rusu, A., Irimie, A., Atanasov, A. G., Slaby, O., et al. (2019) · Cancers · doi:10.3390/cancers11101618 · Cited by 944
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
Chang, S. S., Bochner, B. H., Chou, R., Dreicer, R., Kamat, A. M., Lerner, S. P., Lotan, Y., Meeks, J. J., Michalski, J. M., Morgan, T. M., et al. (2017) · Journal of Urology · doi:10.1016/j.juro.2017.04.086 · Cited by 938
A Five-Gene Signature and Clinical Outcome in Non–Small-Cell Lung Cancer
Chen, H.-Y., Yu, S.-L., Chen, C.-H., Chang, G.-C., Chen, C.-Y., Yuan, A., Cheng, C.-L., Wang, C.-H., Terng, H.-J., Kao, S.-F., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060096 · Cited by 935
An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors
Burgess, A. W., Cho, H.-S., Eigenbrot, C., Ferguson, K. M., Garrett, T. P. J., Leahy, D. J., Lemmon, M. A., Sliwkowski, M. X., Ward, C. W., & Yokoyama, S. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00350-2 · Cited by 909
Chang, M. T., Asthana, S., Gao, S. P., Lee, B. H., Chapman, J. S., Kandoth, C., Gao, J., Socci, N. D., Solit, D. B., Olshen, A. B., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3391 · Cited by 808
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature · doi:10.1038/nature25475 · Cited by 780 · cited 6×
“Unlike with other oncogenes, such as BRAF and KRAS, there is no overall predominant mutation of HER3 and the most common variant differs between tumor types [30].”
BackgroundInfluentialTargeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
Tan, A. C., & Tan, D. S. W. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01626 · Cited by 779
The epidermal growth factor receptor family: Biology driving targeted therapeutics
Wieduwilt, M. J., & Moasser, M. M. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7440-8 · Cited by 751
A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy
Lee-Hoeflich, S. T., Crocker, L., Yao, E., Pham, T., Munroe, X., Hoeflich, K. P., Sliwkowski, M. X., & Stern, H. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0380 · Cited by 629
Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., & Arteaga, C. L. (2001) · PubMed · Cited by 603
Engelman, J. A., Jänne, P. A., Mermel, C., Pearlberg, J., Mukohara, T., Fleet, C., Cichowski, K., Johnson, B. E., & Cantley, L. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409773102 · Cited by 493
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
Shi, F., Telesco, S. E., Liu, Y., Radhakrishnan, R., & Lemmon, M. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002753107 · Cited by 471
Garrett, J. T., Olivares, M. G., Rinehart, C., Granja-Ingram, N. D., Sánchez, V., Chakrabarty, A., Dave, B., Cook, R. S., Pao, W., McKinely, E., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016140108 · Cited by 467
Self-citationLi, M., Zhang, Z., Li, X., Ye, J., Wu, X., Tan, Z., Liu, C., Shen, B., Wang, X.-A., Wu, W., et al. (2014) · Nature Genetics · doi:10.1038/ng.3030 · Cited by 443
Siegel, P. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2149 · Cited by 442
Signal transduction and oncogenesis by ErbB/HER receptors
Marmor, M. D., Skaria, K. B., & Yarden, Y. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.06.002 · Cited by 389 · cited 1×
“This group of receptor tyrosine kinases (RTKs) is involved in cell growth, signaling, and survival [1].”
BackgroundStructure-Based View of Epidermal Growth Factor Receptor Regulation
Ferguson, K. M. (2008) · Annual Review of Biophysics · doi:10.1146/annurev.biophys.37.032807.125829 · Cited by 368
Oncogenic ERBB3 mutations in human cancers.
Jaiswal, B. S., Kljavin, N. M., Stawiski, E. W., Chan, E., Parikh, C., Durinck, S., Chaudhuri, S., Pujara, K., Guillory, J., Edgar, K. A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.012 · Cited by 350
Chakrabarty, A., Sánchez, V., Kuba, M. G., Rinehart, C., & Arteaga, C. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018001108 · Cited by 347
EGF receptor ligands: recent advances
Singh, B., Carpenter, G., & Coffey, R. J. (2016) · F1000Research · doi:10.12688/f1000research.9025.1 · Cited by 323
Jänne, P. A., Baik, C., Su, W.-C., Johnson, M. L., Hayashi, H., Nishio, M., Kim, D.-W., Koczywas, M., Gold, K. A., Steuer, C. E., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0715 · Cited by 289
Motoyama, A. B., Hynes, N. E., & Lane, H. A. (2002) · PubMed · Cited by 286
Targeting HER proteins in cancer therapy and the role of the non-target HER3
Hsieh, A. C., & Moasser, M. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603910 · Cited by 269
What Is the Significance of Variant Histology in Urothelial Carcinoma?
Lobo, N., Shariat, S. F., Guo, C. C., Fernandez, M. I., Kassouf, W., Choudhury, A., Gao, J., Williams, S. B., Galsky, M. D., Taylor, J. A., et al. (2020) · European Urology Focus · doi:10.1016/j.euf.2019.09.003 · Cited by 243
Recondo, G., Bahcall, M., Spurr, L. F., Che, J., Ricciuti, B., Leonardi, G. C., Lo, Y.-C., Li, Y. Y., Lamberti, G., Nguyen, T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3608 · Cited by 220
Ligand-induced ErbB receptor dimerization
Lemmon, M. A. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.10.024 · Cited by 216
Ross, J. S., Fakih, M., Ali, S. M., Elvin, J. A., Schrock, A. B., Suh, J., Vergilio, J., Ramkissoon, S., Severson, E., Daniel, S., et al. (2018) · Cancer · doi:10.1002/cncr.31125 · Cited by 210
Pharmacological targeting of the pseudokinase Her3
Xie, T., Lim, S. M., Westover, K. D., Dodge, M. E., Ercan, D., Ficarro, S. B., Udayakumar, D., Gurbani, D., Tae, H. S., Riddle, S. M., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1658 · Cited by 205
Response to ERBB3-Directed Targeted Therapy in NRG1 -Rearranged Cancers
Drilon, A., Somwar, R., Mangatt, B. P., Edgren, H., Desmeules, P., Ruusulehto, A., Smith, R. S., Delasos, L., Vojnic, M., Plodkowski, A. J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1004 · Cited by 202
Clinical Updates for Colon Cancer Care in 2022
Fabregas, J. C., Ramnaraign, B. H., & George, T. J. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.05.006 · Cited by 192
Campbell, M. R., Amin, D., & Moasser, M. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1218 · Cited by 188
Li, M., Liu, F., Zhang, F., Zhou, W., Jiang, X., Yang, Y., Qu, K., Wang, Y., Ma, Q., Wang, T., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316039 · Cited by 188
Choudhury, N. J., Campanile, A., Antic, T., Yap, K. L., Fitzpatrick, C. A., Wade, J. L., Karrison, T., Stadler, W. M., Nakamura, Y., & O’Donnell, P. H. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.3047 · Cited by 170
Molecular Subtypes of Bladder Cancer
McConkey, D. J., & Choi, W. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0727-5 · Cited by 170
Tao, J. J., Castel, P., Radosevic-Robin, N., Elkabets, M., Auricchio, N., Aceto, N., Weitsman, G., Barber, P., Vojnovic, B., Ellis, H., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2005125 · Cited by 167
HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer
Silva, L. M. D., Simpson, P. T., Smart, C. E., Cocciardi, S., Waddell, N., Lane, A., Morrison, B. J., Vargas, A. C., Healey, S. C., Beesley, J. M., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2603 · Cited by 162
Frogne, T., Benjaminsen, R. V., Sonne‐Hansen, K., Sørensen, B. S., Nexø, E., Lænkholm, A., Rasmussen, L. M., Riese, D. J., de Crémoux, P., Stenvang, J., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0011-8 · Cited by 157
Structures of the HER2–HER3–NRG1β complex reveal a dynamic dimer interface
Diwanji, D. C., Trenker, R., Thaker, T. M., Wang, F., Agard, D. A., Verba, K. A., & Jura, N. (2021) · Nature · doi:10.1038/s41586-021-04084-z · Cited by 156
HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors
Sun, M., Behrens, C., Feng, L., Ozburn, N., Tang, X., Yin, G., Komaki, R., Varella-Garcia, M., Hong, W. K., Aldape, K. D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2921 · Cited by 152
Identification of Metastasis-Associated Receptor Tyrosine Kinases in Non–Small Cell Lung Cancer
Müller-Tidow, C., Diederichs, S., Bulk, E., Pohle, T., Steffen, B., Schwäble, J., Plewka, S., Thomas, M., Metzger, R., Schneider, P. M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3388 · Cited by 139
Scharpenseel, H., Hanssen, A., Loges, S., Mohme, M., Bernreuther, C., Peine, S., Lamszus, K., Goy, Y., Petersen, C., Westphal, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43678-6 · Cited by 132
HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation
Vaught, D. B., Stanford, J. C., Young, C., Hicks, D. J., Wheeler, F., Rinehart, C., Sánchez, V., Koland, J., Muller, W. J., Arteaga, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3594 · Cited by 129 · cited 1×
“Loss of HER3 prevents HER2-mediated transformation of mammary epithelium in transgenic mice [65].”
BackgroundMontero, J. C., Barrueco, R. R., Ocaña, A., Díaz-Rodríguez, E., Esparís-Ogando, A., & Pandiella, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5133 · Cited by 128
Yi, E. S., Harclerode, D. L., Gondo, M., Stephenson, M. A., Brown, R. W., Younes, M., & Cagle, P. T. (1997) · PubMed · Cited by 128
Littlefield, P., Liu, L., Mysore, V., Shan, Y., Shaw, D. E., & Jura, N. (2014) · Science Signaling · doi:10.1126/scisignal.2005786 · Cited by 126
ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics
Kiavué, N., Cabel, L., Melaabi, S., Bataillon, G., Callens, C., Lerebours, F., Pierga, J., & Bidard, F. (2019) · Oncogene · doi:10.1038/s41388-019-1001-5 · Cited by 122
Li, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa026 · Cited by 119 · cited 1×
“Although HER2 is HER3′s preferred dimerization partner, the commonality of HER3 amplifications and mutations may leave it with a higher possibility of dimerizing with EGFR [97].”
BackgroundThirty Years of HER3: From Basic Biology to Therapeutic Interventions
Haikala, H. M., & Jänne, P. A. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4465 · Cited by 115
Kodack, D. P., Askoxylakis, V., Ferraro, G. B., Sheng, Q., Badeaux, M., Goel, S., Qi, X., Shankaraiah, R., Cao, Z. A., Ramjiawan, R. R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal4682 · Cited by 110
Yonesaka, K., Tanizaki, J., Maenishi, O., Haratani, K., Kawakami, H., Tanaka, K., Hayashi, H., Sakai, K., Chiba, Y., Tsuya, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3359 · Cited by 110
Hanker, A. B., Brown, B. P., Meiler, J., Marín, A., Jayanthan, H. S., Ye, D., Lin, C.-C., Akamatsu, H., Lee, K.-M., Chatterjee, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.001 · Cited by 105
Fitzgerald, J. B., Johnson, B. W., Baum, J., Adams, S., Iadevaia, S., Tang, J., Rimkunas, V., Xu, L., Kohli, N., Rennard, R., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0255 · Cited by 103
LoRusso, P., Jänne, P. A., Oliveira, M., Rizvi, N., Malburg, L., Keedy, V., Yee, L., Copigneaux, C., Hettmann, T., Wu, C.-Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3051 · Cited by 92
Lee, D., Yu, M., Lee, E., Kim, H., Yang, Y., Kim, K., Pannicia, C., Kurie, J. M., & Threadgill, D. W. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36435 · Cited by 91
The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family
Kennedy, S. P., Hastings, J. F., Han, J. Z. R., & Croucher, D. R. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00088 · Cited by 80
Schneeweiß, A., Park‐Simon, T., Albanell, J., Lassen, U., Cortés, J., Dieras, V. C., May, M., Schindler, C., Marmé, F., Cejalvo, J. M., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0562-4 · Cited by 80
Claus, J., Patel, G. S., Autore, F., Colomba, A., Weitsman, G. E., Soliman, T. N., Roberts, S. K., Zanetti-Domingues, L. C., Hirsch, M., Collu, F., et al. (2018) · eLife · doi:10.7554/elife.32271 · Cited by 75
AXL is an oncotarget in human colorectal cancer
Martinelli, E., Martini, G., Cardone, C., Troiani, T., Liguori, G., Vitagliano, D., Napolitano, S., Morgillo, F., Rinaldi, B., Melillo, R. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3962 · Cited by 74
The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium
Balko, J. M., Miller, T. W., Morrison, M. M., Hutchinson, K., Young, C., Rinehart, C., Sánchez, V., Jee, D., Polyak, K., Prat, A., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115802109 · Cited by 73
Meulendijks, D., Jacob, W., Martinez-Garcia, M., Taus, A., Lolkema, M. P., Voest, E. E., Langenberg, M. H. G., Fleitas Kanonnikoff, T., Cervantes, A., De Jonge, M. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1683 · Cited by 73
ErbB3 downregulation enhances luminal breast tumor response to antiestrogens
Morrison, M. M., Hutchinson, K. E., Williams, M. M., Stanford, J. C., Balko, J. M., Young, C. D., Kuba, M. G., Sanchez, V. M., Williams, A. J., Hicks, D. J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66764 · Cited by 69
Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients
Berghoff, A. S., Bartsch, R., Preusser, M., Ricken, G., Steger, G. G., Bagó-Horváth, Z., Rudas, M., Streubel, B., Dubsky, P. C., Gnant, M., et al. (2014) · The Breast · doi:10.1016/j.breast.2014.06.011 · Cited by 68
Romaniello, D., Marrocco, I., Nataraj, N. B., Ferrer, I., Garcia, D. D., Vaknin, I., Oren, R., Lindzen, M., Ghosh, S., Kreitman, M., et al. (2020) · Cancers · doi:10.3390/cancers12092394 · Cited by 67
Jiang, N., Wang, D., Hu, Z., Shin, H. J. C., Qian, G., Rahman, M. A., Zhang, H., Amin, A. R. M. R., Nannapaneni, S., Wang, X., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1093 · Cited by 62
Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer
Ma, S., Zhang, L., Ren, Y., Dai, W., Chen, T., Luo, L., Zeng, J., Mi, K., Lang, J., & Cao, B. (2021) · Oncogene · doi:10.1038/s41388-021-01734-4 · Cited by 62
Hutcheson, I. R., Goddard, L., Barrow, D., McClelland, R. A., Francies, H. E., Knowlden, J. M., Nicholson, R. I., & Gee, J. M. W. (2011) · Breast Cancer Research · doi:10.1186/bcr2848 · Cited by 60
Juric, D., Dienstmann, R., Cervantes, A., Hidalgo, M., Messersmith, W., Blumenschein, G. R., Tabernero, J., Roda, D., Calles, A., Jimeno, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2412 · Cited by 59
Ogden, A., Bhattarai, S., Sahoo, B., Mongan, N. P., Alsaleem, M. A., Green, A. R., Aleskandarany, M. A., Ellis, I. O., Pattni, S., Li, X., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-59514-1 · Cited by 58
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Gandullo‐Sánchez, L., Capone, E., Ocaña, A., Iacobelli, S., Sala, G., & Pandiella, A. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911498 · Cited by 58
Sequist, L. V. D., Gray, J. E., Harb, W. A., López-Chávez, A., Doebele, R. C., Modiano, M., Jackman, D. M., Baggstrom, M. Q., Atmaca, A., Felip, E., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0695 · Cited by 56
Roles for neuregulins in human cancer
Stove, C. P., & Bracke, M. (2005) · Clinical & Experimental Metastasis · doi:10.1007/s10585-004-6917-6 · Cited by 54
Lédel, F., Hallström, M., Ragnhammar, P., Öhrling, K., & Edler, D. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.11.008 · Cited by 52
Li, X., Xu, Y., Ding, Y., Li, C., Zhao, H. W., Wang, J., & Meng, S. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0862-5 · Cited by 50
Suenaga, A., Takada, N., Okada, M., Ichikawa, M., Yu, X., Tomii, K., Okimoto, N., Futatsugi, N., Narumi, T., Shirouzu, M., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410436200 · Cited by 48
Gan, H. K., Millward, M., Jalving, M., Garrido‐Laguna, I., Lickliter, J. D., Schellens, J. H. M., Lolkema, M. P., van Herpen, C. M. L., Hug, B. A., Tang, L., et al. (2021) · The Oncologist · doi:10.1002/onco.13860 · Cited by 47
Servidei, T., Riccardi, A., Mozzetti, S., Ferlini, C., & Riccardi, R. (2008) · International Journal of Cancer · doi:10.1002/ijc.23902 · Cited by 45
Wakui, H., Yamamoto, N., Nakamichi, S., Tamura, Y., Nokihara, H., Yamada, Y., & Tamura, T. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2375-2 · Cited by 43
Nishio, M., Horiike, A., Murakami, H., Yamamoto, N., Kaneda, H., Nakagawa, K., Horinouchi, H., Nagashima, M., Sekiguchi, M., & Tamura, T. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.03.010 · Cited by 40
Wu, Y., Zhang, Y., Wang, M., Li, Q., Qu, Z., Shi, V., Kraft, P., Kim, S. H., Gao, Y. J., Pak, J., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0838 · Cited by 40
Activating HER3 mutations in breast cancer
Mishra, R., Alanazi, S., Yuan, L., Solomon, T., Thaker, T. M., Jura, N., & Garrett, J. T. (2018) · Oncotarget · doi:10.18632/oncotarget.25576 · Cited by 40
Self-citationFujiwara, S., Ibusuki, M., Yamamoto, S., Yamamoto, Y., & Iwase, H. (2012) · Breast Cancer · doi:10.1007/s12282-012-0415-5 · Cited by 37
Reynolds, K. L., Bedard, P. L., Lee, S., Lin, C., Tabernero, J. M., Alsina, M., Cohen, E. E. W., Baselga, J. M., Blumenschein, G. R., Graham, D. M., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3641-6 · Cited by 37
Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation
Frazier, N. M., Brand, T. M., Gordan, J. D., Grandis, J. R., & Jura, N. (2018) · Oncogene · doi:10.1038/s41388-018-0537-0 · Cited by 37
Lee, H., Lee, H., Chin, H., Kim, K., & Lee, D. (2014) · Oncotarget · doi:10.18632/oncotarget.2094 · Cited by 36
Schultink, A. H. M. D. V., Doornbos, R. P., Bakker, A. B. H., Bol, K., Throsby, M., Geuijen, C. A. W., Maussang, D., Schellens, J. H. M., Beijnen, J. H., & Huitema, A. D. R. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0593-x · Cited by 36
Collier, T. S., Diraviyam, K., Monsey, J., Shen, W., Sept, D., & Bose, R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.474882 · Cited by 35
Massarweh, S. A., Tham, Y. L., Huang, J., Sexton, K. R., Weiss, H. L., Tsimelzon, A. I., Beyer, A. R., Rimawi, M. F., Cai, W. Y., Hilsenbeck, S. G., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1679-8 · Cited by 35
Janne, P. A., Baik, C. S., Su, W., Johnson, M. L., Hayashi, H., Nishio, M., Kim, D., Koczywas, M., Gold, K. A., Steuer, C. E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.9007 · Cited by 33
Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer
Bidard, F., Ng, C. K. Y., Cottu, P. H., Piscuoglio, S., Escalup, L., Sakr, R. A., Reyal, F., Mariani, P., Lim, R. S., Wang, L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv217 · Cited by 30
A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance
Al‐Akhrass, H., Conway, J. R. W., Poulsen, A. S. A., Paatero, I., Kaivola, J., Padzik, A., Andersen, O. M., & Ivaska, J. (2021) · Oncogene · doi:10.1038/s41388-020-01604-5 · Cited by 30
Berdiel‐Acer, M., Maia, A. R. R., Hristova, Z., Borgoni, S., Vetter, M., Burmester, S., Becki, C., Michels, B. E., Abnaof, K., Binenbaum, I., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01719-3 · Cited by 30
Bacco, F. D., Orzan, F., Erriquez, J., Casanova, E., Barault, L., Albano, R., D’Ambrosio, A., Bigatto, V., Reato, G., Patanè, M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109455 · Cited by 30
HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
Styczen, H., Nagelmeier, I., Beissbarth, T., Nietert, M., Homayounfar, K., Sprenger, T., Boczek, U., Stanek, K., Kitz, J., Wolff, H. A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3527 · Cited by 29
Garufi, G., Carbognin, L., Schettini, F., Seguí, E., Leone, A. D., Franco, A., Paris, I., Scambia, G., Tortora, G., & Fabi, A. (2022) · Cancers · doi:10.3390/cancers14174064 · Cited by 29
Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer
Tamura, S., Wang, Y., Veeneman, B. A., Hovelson, D. H., Bankhead, A., Broses, L. J., Hiles, G. L., Liebert, M., Rubin, J. R., Day, K. C., et al. (2018) · Bladder Cancer · doi:10.3233/blc-170144 · Cited by 27
Gong, Y., & Zhao, X. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)01174-8 · Cited by 26
Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells
Bosch-Vilaró, A., Jacobs, B., Pomella, V., Asbagh, L. A., Kirkland, R. E., Michel, J., Singh, S., Liu, X., Kim, P., Weitsman, G. E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13834 · Cited by 26
Nielsen, T. Ø., Borre, M., Nexø, E., & Sørensen, B. S. (2014) · British Journal of Urology · doi:10.1111/bju.12658 · Cited by 25
ErbB3 mRNA Expression Correlated with Specific Clinicopathologic Features of Japanese Lung Cancers
Kawano, O., Sasaki, H., Endo, K., Suzuki, E., Haneda, H., Yukiue, H., Kobayashi, Y., Yano, M., & Fujii, Y. (2007) · Journal of Surgical Research · doi:10.1016/j.jss.2007.05.030 · Cited by 25
Tanimura, K., Yamada, T., Okada, K., Nakai, K., Horinaka, M., Katayama, Y., Morimoto, K., Ogura, Y., Takeda, T., Shiotsu, S., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-021-00250-8 · Cited by 25
Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer
Umelo, I. A., Noeparast, A., Chen, G., Renard, M., Geers, C., Vansteenkiste, J., Giron, P., Wever, O. D., Teugels, E., & Grève, J. D. (2015) · Oncotarget · doi:10.18632/oncotarget.6585 · Cited by 23
A germline ERBB3 variant is a candidate for predisposition to erythroid MDS/erythroleukemia
Braunstein, E. M., Li, R., Sobreira, N. L. D. M., Marosy, B. A., Hetrick, K. N., Doheny, K. F., Gocke, C. D., Valle, D. L., Brodsky, R. A., & Cheng, L. (2016) · Leukemia · doi:10.1038/leu.2016.173 · Cited by 22
HER3 expression and MEK activation in non-small-cell lung carcinoma
Manickavasagar, T., Yuan, W., Carreira, S., Gürel, B., Miranda, S., Ferreira, A., Crespo, M., Riisnaes, R., Baker, C., O'Brien, M. E. R., et al. (2021) · Lung Cancer Management · doi:10.2217/lmt-2020-0031 · Cited by 22
Weickhardt, A. J., Lau, D. K., Hodgson‐Garms, M., Lavis, A., Jenkins, L. J., Vukelic, N., Ioannidis, P., Luk, I. Y., & Mariadason, J. M. (2022) · BMC Cancer · doi:10.1186/s12885-022-09478-4 · Cited by 22
Seligmann, J. F., Elliott, F., Richman, S. D., Hemmings, G., Brown, S., Jacobs, B., Williams, C. J. M., Tejpar, S., Barrett, J. H., Quirke, P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.476 · Cited by 21
Berghoff, A. S., Magerle, M., Ilhan‐Mutlu, A., Dinhof, C., Widhalm, G., Dieckman, K., Marosi, C., Wöehrer, A., Hackl, M., Zöchbauer‐Müller, S., et al. (2013) · Apmis · doi:10.1111/apm.12063 · Cited by 20
Schultink, A. H. M. D. V., Bol, K., Doornbos, R. P., Murat, A., Wasserman, E., Dorlo, T. P. C., Schellens, J. H. M., Beijnen, J. H., & Huitema, A. D. R. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00858-2 · Cited by 20
Miano, C., Morselli, A., Pontis, F., Bongiovanni, C., Sacchi, F., Pra, S. D., Romaniello, D., Tassinari, R., Sgarzi, M., Pantano, E., et al. (2022) · Cancers · doi:10.3390/cancers14071603 · Cited by 17
Met–HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells
Stern, Y. E., Al‐Ghabkari, A., Monast, A., Fiset, B., Aboualizadeh, F., Yao, Z., Štagljar, I., Walsh, L. A., Duhamel, S., & Park, M. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04149-w · Cited by 17
A small molecule inhibitor of HER3: a proof-of-concept study
Colomba, A., Fitzek, M., George, R., Weitsman, G. E., Roberts, S. K., Zanetti-Domingues, L. C., Hirsch, M., Rolfe, D. J., Mehmood, S., Madin, A., et al. (2020) · Biochemical Journal · doi:10.1042/bcj20200496 · Cited by 16
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers
Milewska, M., Cremona, M., Morgan, C., O’Shea, J., Carr, A., Vellanki, S. H., Hopkins, A. M., Toomey, S., Madden, S. F., Hennessy, B. T., et al. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017746040 · Cited by 15
Bauman, J. E., Julian, R. A., Saba, N. F., Wise-Draper, T. M., Adkins, D. R., O’Brien, P., Fidler, M. J., Gibson, M. K., Duvvuri, U., Heath-Chiozzi, M. E., et al. (2022) · Cancers · doi:10.3390/cancers14102355 · Cited by 15
Taniguchi, H., Akagi, K., Dotsu, Y., Yamada, T., Ono, S., Imamura, E., Gyotoku, H., Takemoto, S., Yamaguchi, H., Sen, T., et al. (2022) · Cancer Science · doi:10.1111/cas.15579 · Cited by 15
Rathore, M., Zhang, W., Wright, M., Bhattacharya, R., Fan, F., Vaziri-Gohar, A., Winter, J., Wang, Z., Markowitz, S. D., Willis, J., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0633 · Cited by 14
Gao, W., Hou, L., Yang, Y. P., Xie, H., Yang, Y., Li, Z., Zhao, H., Sun, Y., & Su, B. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s107272 · Cited by 13
Berlin, J. D., Tolcher, A. W., Ding, C., Whisenant, J. G., Horak, I. D., Wood, D. L., Nadler, P. I., Hansen, U. H., Lantto, J., Skartved, N. J. Ø., et al. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01217-7 · Cited by 12
Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer
Papadimitropoulou, A., Vellón, L., Atlas, E., Steen, T. V., Cuyàs, E., Verdura, S., Espinoza, I. C., Menéndez, J. A., & Lupu, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207737 · Cited by 11
Nazari, M., Emamzadeh, R., Jahanpanah, M., Yazdani, E., & Radmanesh, R. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.08.150 · Cited by 10
Prognostic significance of serum ERBB3 and ERBB4 mRNA in lung adenocarcinoma patients
Masroor, M., Javid, J., Mir, R., Prasant, Y., Imtiyaz, A., Mariyam, Z., Mohan, A., Ray, P., & Saxena, A. (2015) · Tumor Biology · doi:10.1007/s13277-015-3859-3 · Cited by 9
Soluble HER3 predicts survival in bladder cancer patients
Memon, A. A., Gilliver, S. C., Borre, M., Sundquist, J., Sundquist, K., Nexø, E., & Sørensen, B. S. (2017) · Oncology Letters · doi:10.3892/ol.2017.7470 · Cited by 9
Buccinnà, B., Ramondetti, C., & Piccinini, M. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115228 · Cited by 9
Landscape of Epidermal Growth Factor Receptor Heterodimers in Brain Metastases
Lim, M., Nguyen, T. H., Niland, C., Reid, L., Jat, P., Saunus, J. M., & Lakhani, S. R. (2022) · Cancers · doi:10.3390/cancers14030533 · Cited by 8
Toulany, M., Iida, M., Lettau, K., Coan, J. P., Rebholz, S., Khozooei, S., Harari, P. M., & Wheeler, D. L. (2022) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2022.07.008 · Cited by 8
ErbB3 Ligand Heregulin1 Is a Major Mitogenic Factor for Uncontrolled Lung Cancer Cell Proliferation
Ma, S., Jia, S., Ren, Y., Cao, B., Zha, X., He, J., & Chen, C. (2019) · Neoplasia · doi:10.1016/j.neo.2019.02.001 · Cited by 7
McInerney-Leo, A. M., Chew, H. Y., Inglis, P.-L., Leo, P. J., Joseph, S. R., Cooper, C. L., Okano, S., Hassall, T., Anderson, L. K., Bowman, R., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab172 · Cited by 7
Rojas, C. M., McGill, M. P., Salvador, A. C., Bautz, D. J., & Threadgill, D. W. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009931 · Cited by 5
Meneses‐Lorente, G., McIntyre, C., Hsu, J., Thomas, M., Jacob, W., Adessi, C., & Weisser, M. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3328-3 · Cited by 4
Lyu, H., Ruan, S., Tan, C., & Liu, B. (2022) · Cancer Research · doi:10.1158/1538-7445.am2022-3272 · Cited by 3
Yan, F., Jiang, Q., Ru, B., Fei, X.-J., Ruan, J., & Zhang, X. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i8.2497 · Cited by 1
Cited by
HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review
Pan, L., Li, J., Xu, Q., Gao, Z., Yang, M., Wu, X., & Li, X. (2024) · Medicine · doi:10.1097/md.0000000000038508 · Cited by 174
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“…displays intrinsically low kinase activity and must dimerize with either another EGFR-family member, including HER2 and EGFR, or a non-EGFR receptor tyrosine kinase (RTKs), including fibroblast growth factor receptor (FGFR), MET, or Axl to stimulate cell survival and proliferation signaling [38].”
BackgroundEmerging importance of HER3 in tumorigenesis and cancer therapy
Garrett, J. T., Tendler, S., Feroz, W., Kilroy, M. K., & Yu, H. A. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01008-y · Cited by 46
Self-citationTargeting HER3 to overcome EGFR TKI resistance in NSCLC
Chen, Q., Jia, G., Zhang, X., & Ma, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1332057 · Cited by 40
Triple-negative breast cancer: from none to multiple therapeutic targets in two decades
Carvalho, F. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1244781 · Cited by 34
Metadata
- Authors
- Kilroy, M. K., Park, S., Feroz, W., Patel, H., Mishra, R., Alanazi, S., & Garrett, J. T.
- Affiliations
- University of Cincinnati (US)
- Department of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, USA
- Harold C. Simmons Comprehensive Cancer Center (US)
- Corresponding author
- Garrett, Joan T.
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2022-12-14
- Volume
- 14
- Issue
- 24
- Pages
- 6174
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC9776947
- OpenAlex
- W4311793976
- Cited by
- 21
- References
- 155
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 10 · 2023: 1
- FWCI
- 0.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- American Cancer Society (RSG-20-071-01-TBG)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- HER3, ErbB receptors, bladder cancer, breast cancer, colorectal cancer, lung cancer, tumor progression, targeted therapy resistance, genetic alterations
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.